Identification of Serum Soluble ST2 Receptor as a Novel

Circulation

107, 721-726

DOI: 10.1161/01.cir.0000047274.66749.fe

Citation Report

#	Article	IF	Citations
1	Practical considerations for BNP use. Heart Failure Reviews, 2003, 8, 369-373.	1.7	4
2	Cardiovascular genomics. Cardiovascular Pathology, 2003, 12, 249-254.	0.7	1
4	Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction. Circulation, 2004, 109, 2186-2190.	1.6	378
5	Cell mechanics and mechanotransduction: pathways, probes, and physiology. American Journal of Physiology - Cell Physiology, 2004, 287, C1-C11.	2.1	473
6	Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Medicine, 2004, 30, 1468-73.	3.9	158
7	Recent advances in the diagnosis of heart failure. Current Cardiology Reports, 2004, 6, 205-210.	1.3	2
8	Novel markers for heart failure diagnosis and prognosis. Current Opinion in Cardiology, 2005, 20, 201-210.	0.8	71
9	IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity, 2005, 23, 479-490.	6.6	3,161
10	The Interleukinâ€1 Receptor Family. Vitamins and Hormones, 2006, 74, 229-254.	0.7	90
11	Cardiovascular Biomarkers. , 2006, , .		5
12	Plasma BNP/NT-proBNP Assays: What Do They Target and What Else Might They Recognize?. Heart Failure Clinics, 2006, 2, 291-298.	1.0	4
13	Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2006, 48, 1217-1224.	1.2	500
14	Physiological genomics of cardiac disease: quantitative relationships between gene expression and left ventricular hypertrophy. Physiological Genomics, 2006, 27, 86-94.	1.0	37
15	Prorenin Induces Intracellular Signaling in Cardiomyocytes Independently of Angiotensin II. Hypertension, 2006, 48, 564-571.	1.3	228
16	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. Circulation, 2007, 116, e99-109.	1.6	234
17	Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea. Journal of the American College of Cardiology, 2007, 50, 607-613.	1.2	461
18	ILâ€33 is a chemoattractant for human Th2 cells. European Journal of Immunology, 2007, 37, 2779-2786.	1.6	293
19	ST2 in Emergency Department Chest Pain Patients With Potential Acute Coronary Syndromes. Annals of Emergency Medicine, 2007, 50, 153-158.e1.	0.3	35

#	Article	IF	Citations
20	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. Clinical Biochemistry, 2008, 41, 210-221.	0.8	61
21	Biomarkers in Heart Failure. New England Journal of Medicine, 2008, 358, 2148-2159.	13.9	1,111
22	The search for new cardiovascular biomarkers. Nature, 2008, 451, 949-952.	13.7	298
23	The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nature Reviews Drug Discovery, 2008, 7, 827-840.	21.5	634
25	Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2008, 52, 1458-1465.	1.2	335
26	Serum Soluble ST2 as a Biochemical Marker of Acute Heart Failure. Journal of the American College of Cardiology, 2008, 52, 1466-1467.	1.2	22
27	Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic Load. Journal of the American College of Cardiology, 2008, 52, 2166-2174.	1.2	207
28	Biomarkers for cardiovascular disease: challenges and future directions. Trends in Molecular Medicine, 2008, 14, 261-267.	3.5	33
29	Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart Failure. Journal of Cardiac Failure, 2008, 14, 732-738.	0.7	179
30	Independent and incremental prognostic value of multimarker testing in acute dyspnea: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clinica Chimica Acta, 2008, 392, 41-45.	0.5	52
31	Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine, 2008, 41, 114-120.	1.4	58
32	IL-33 reduces the development of atherosclerosis. Journal of Experimental Medicine, 2008, 205, 339-346.	4.2	574
33	Increased Plasma Concentrations of Soluble ST2 are Predictive for 1-Year Mortality in Patients with Acute Destabilized Heart Failure. Clinical Chemistry, 2008, 54, 752-756.	1.5	153
34	Multimarker Approach in Cardiovascular Risk Prediction. Disease Markers, 2009, 26, 273-285.	0.6	18
35	Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling. Circulation: Heart Failure, 2009, 2, 684-691.	1.6	306
36	Novel biomarkers in heart failure: an overview. Biomarkers in Medicine, 2009, 3, 453-463.	0.6	8
38	Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute Dyspnea. Circulation: Heart Failure, 2009, 2, 311-319.	1.6	160
39	ST2 protein in heart disease: from discovery to mechanisms and prognostic value. Biomarkers in Medicine, 2009, 3, 495-511.	0.6	38

#	Article	IF	Citations
40	Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma â€" The Presageâ„¢ ST2 assay. Clinica Chimica Acta, 2009, 409, 33-40.	0.5	214
41	Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology, 2009, 54, 2174-2179.	1.2	205
42	Large-scale studies to identify biomarkers for heart disease: a role for proteomics?. Expert Opinion on Medical Diagnostics, 2009, 3, 133-141.	1.6	2
43	ST2 and Adrenomedullin in Heart Failure. Heart Failure Clinics, 2009, 5, 515-527.	1.0	6
44	What We May Expect from Biomarkers in Heart Failure. Heart Failure Clinics, 2009, 5, 463-470.	1.0	16
45	Evidence of Association of Interleukin-1 Receptor-Like 1 Gene Polymorphisms with Chronic Rhinosinusitis. American Journal of Rhinology and Allergy, 2009, 23, 377-384.	1.0	55
46	The Right Ventricle Under Pressure. Chest, 2009, 135, 794-804.	0.4	604
47	Genetics of Interleukin 1 Receptor-Like 1 in Immune and Inflammatory Diseases. Current Genomics, 2010, 11, 591-606.	0.7	46
48	Natriuretic peptides in heart failure. Therapy: Open Access in Clinical Medicine, 2010, 7, 355-365.	0.2	0
49	Early detection of myocardial dysfunction and heart failure. Nature Reviews Cardiology, 2010, 7, 334-344.	6.1	82
50	Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Medicine, 2010, 36, 630-637.	3.9	107
51	ST2: A Novel Remodeling Biomarker in Acute and Chronic Heart Failure. Current Heart Failure Reports, 2010, 7, 9-14.	1.3	93
52	Biomarkers in heart failure: a clinical review. Heart Failure Reviews, 2010, 15, 251-273.	1.7	20
53	Biomarkers of inflammation in heart failure. Heart Failure Reviews, 2010, 15, 331-341.	1.7	169
54	KU812 cells provide a novel in vitro model of the human IL-33/ST2L axis: Functional responses and identification of signaling pathways. Experimental Cell Research, 2010, 316, 2527-2537.	1.2	20
55	Biomarkers of Heart Failure. Congestive Heart Failure, 2010, 16, S19-24.	2.0	32
56	Characterization of ST2 transgenic mice with resistance to ILâ€33. European Journal of Immunology, 2010, 40, 2632-2642.	1.6	32
58	Identification and functionality of proteomes secreted by rat cardiac stem cells and neonatal cardiomyocytes. Proteomics, 2010, 10, 245-253.	1.3	98

#	Article	IF	Citations
59	Interleukin family member ST2 and mortality in acute dyspnoea. Journal of Internal Medicine, 2010, 268, 493-500.	2.7	37
60	ILâ€33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clinical and Experimental Allergy, 2010, 40, 200-208.	1.4	169
61	Disease-associated functions of IL-33: the new kid in the IL-1 family. Nature Reviews Immunology, 2010, 10, 103-110.	10.6	885
62	Interleukin-33 Induces Protective Effects in Adipose Tissue Inflammation During Obesity in Mice. Circulation Research, 2010, 107, 650-658.	2.0	285
63	Plasma Soluble Corin in Patients With Heart Failure. Circulation: Heart Failure, 2010, 3, 207-211.	1.6	134
64	Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?. Cardiovascular Research, 2010, 85, 649-660.	1.8	66
65	Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovascular Research, 2010, 87, 769-777.	1.8	111
66	Use of Biomarkers in Evaluation of Patients with Heart Failure. Contributions To Nephrology, 2010, 164, 88-117.	1.1	2
67	Interleukin-33, a Novel Member of the IL-1/IL-18 Cytokine Family, in Cardiology and Cardiac Surgery. Thoracic and Cardiovascular Surgeon, 2010, 58, 443-449.	0.4	18
68	IL-33 and IL-33 Receptors in Host Defense and Diseases. Allergology International, 2010, 59, 143-160.	1.4	183
69	Serum Soluble ST2. Journal of the American College of Cardiology, 2010, 55, 243-250.	1.2	256
70	Found in Translation. Journal of the American College of Cardiology, 2010, 55, 251-253.	1.2	14
71	Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure. Revista Espanola De Cardiologia (English Ed), 2010, 63, 1171-1178.	0.4	31
72	Uridine triphosphate (UTP) induces profibrotic responses in cardiac fibroblasts by activation of P2Y2 receptors. Journal of Molecular and Cellular Cardiology, 2010, 49, 362-369.	0.9	40
73	Association of ST2 levels with cardiac structure and function and mortality in outpatients. American Heart Journal, 2010, 160, 721-728.	1.2	93
74	Biomarkers in heart failure. Heart, 2010, 96, 314-320.	1.2	28
75	ST2: a novel biomarker for heart failure. Expert Review of Molecular Diagnostics, 2010, 10, 459-464.	1.5	60
77	New insights for the diagnosis and management of right ventricular failure, from molecular imaging to targeted right ventricular therapy. Current Opinion in Cardiology, 2010, 25, 131-140.	0.8	36

#	Article	IF	Citations
78	Diagnosing Destabilized Heart Failure in the Emergency Setting. Molecular Diagnosis and Therapy, 2011, 15, 327-340.	1.6	1
79	Novel biomarkers in human terminal heart failure and under mechanical circulatory support. Biomarkers, 2011, 16, S31-S41.	0.9	23
80	The Use of Biomarkers in the Evaluation of Heart Failure. , 2011, , 545-559.		1
81	Biomarkers of Heart Failure in Myocarditis and Dilated Cardiomyopathy. , 2011, , .		4
82	Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation. Current Pharmaceutical Design, 2011, 17, 1-8.	0.9	36
83	Biomarkers in Advanced Heart Failure: Diagnostic and Therapeutic Insights. Congestive Heart Failure, 2011, 17, 169-174.	2.0	13
84	The IL-33/ST2 pathway â€" A new therapeutic target in cardiovascular disease. , 2011, 131, 179-186.		137
85	Usefulness of Soluble Concentrations of Interleukin Family Member ST2 as Predictor of Mortality in Patients With Acutely Decompensated Heart Failure Relative to Left Ventricular Ejection Fraction. American Journal of Cardiology, 2011, 107, 259-267.	0.7	185
86	Established and novel biomarkers in ST-elevation myocardial infarction. Future Cardiology, 2011, 7, 523-546.	0.5	0
87	IL-33 åŠå…¶ä¸æž¢ç¥žç»ç³»ç»Ÿä¸½œç”¨çš„ç”Ÿç©¿è¿›å±•. Neuroscience Bulletin, 2011, 27, 351-357.	1.5	34
88	Novel Biomarkers in Acute Heart Failure. Current Heart Failure Reports, 2011, 8, 206-211.	1.3	37
89	Toll/Interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovascular Diabetology, 2011, 10, 101.	2.7	52
90	Role of IL-33 in inflammation and disease. Journal of Inflammation, 2011, 8, 22.	1.5	368
91	Cardiovascular proteomics: Translational studies to develop novel biomarkers in heart failure and left ventricular remodeling. Proteomics - Clinical Applications, 2011, 5, 57-66.	0.8	24
92	Risk stratification and short-term prognosis in acute heart failure syndromes: A review of novel biomarkers. Biomarkers, 2011, 16, 379-392.	0.9	16
93	High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure, 2011, 4, 180-187.	1.6	319
94	Prognostic Utility of ST2 in Patients with Acute Dyspnea and Preserved Left Ventricular Ejection Fraction. Clinical Chemistry, 2011, 57, 874-882.	1.5	81
95	IL-33 Exacerbates Acute Kidney Injury. Journal of the American Society of Nephrology: JASN, 2011, 22, 2057-2067.	3.0	128

#	Article	IF	Citations
96	Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1515-8.	1.4	26
97	ST2 and IL-33 in Pregnancy and Pre-Eclampsia. PLoS ONE, 2011, 6, e24463.	1.1	78
98	IL-1 family cytokines trigger sterile inflammatory disease. Frontiers in Immunology, 2012, 3, 315.	2.2	134
99	Soluble ST2 Is Regulated by p75 Neurotrophin Receptor and Predicts Mortality in Diabetic Patients With Critical Limb Ischemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, e149-60.	1.1	42
100	Serial Monitoring of Soluble Interleukin Family Member ST2 in Patients with Acutely Decompensated Heart Failure. Cardiology, 2012, 122, 158-166.	0.6	67
101	Role of ST2 in Nonâ€“ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial. Clinical Chemistry, 2012, 58, 257-266.	1.5	140
102	IL-33 Independently Induces Eosinophilic Pericarditis and Cardiac Dilation. Circulation: Heart Failure, 2012, 5, 366-375.	1.6	51
103	Successful transcatheter aortic valve implantation (TAVI) is associated with transient left ventricular dysfunction. Heart, 2012, 98, 1641-1646.	1.2	35
104	IL-33: a Janus cytokine: Table 1. Annals of the Rheumatic Diseases, 2012, 71, i101-i104.	0.5	87
105	Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. European Journal of Heart Failure, 2012, 14, 268-277.	2.9	110
106	Prognostic Utility of Novel Biomarkers of Cardiovascular Stress. Circulation, 2012, 126, 1596-1604.	1.6	414
107	Emerging Biomarkers in Heart Failure. Clinical Chemistry, 2012, 58, 127-138.	1.5	227
108	The ST2 Pathway Is Involved in Acute Pancreatitis. American Journal of Pathology, 2012, 180, 2330-2339.	1.9	27
109	Hypertensive left ventricular hypertrophy is highly arrhythmogenic â€" Compelling indication for some beta blockers?. International Journal of Cardiology, 2012, 159, 160-161.	0.8	2
110	Short term effect of CRT on biomarkers of cardiac remodelling and fibrosis: NT-proBNP, sST2, galectin-3, and a marker of oxidative stress â€" ceruloplasmin â€" A pilot study. International Journal of Cardiology, 2012, 159, 159-160.	0.8	5
111	Corin in clinical laboratory diagnostics. Clinica Chimica Acta, 2012, 413, 378-383.	0.5	60
112	Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit â€" The Linz Intensive Care Unit (LICU) study. Clinica Chimica Acta, 2012, 413, 587-593.	0.5	16
113	Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress. Journal of Translational Medicine, 2012, 10, 120.	1.8	40

#	Article	IF	Citations
114	Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cells. Cellular and Molecular Immunology, 2012, 9, 399-409.	4.8	21
115	Where Genome Meets Phenome: Rationale for Integrating Genetic and Protein Biomarkers in the Diagnosis and Management of Dilated Cardiomyopathy and Heart Failure. Journal of the American College of Cardiology, 2012, 60, 283-289.	1.2	76
116	Experimental biomarkers in heart failure: an update. Expert Review of Cardiovascular Therapy, 2012, 10, 1119-1132.	0.6	3
117	Mid-Regional Pro-Adrenomedullin in Acute Heart Failure: A Better Biomarker or Just Another Biomarker?. Current Heart Failure Reports, 2012, 9, 244-251.	1.3	29
118	Biomarkers. Heart Failure Clinics, 2012, 8, 207-224.	1.0	7
119	Growth differentiation factor 15, ST2, highâ€sensitivity troponin T, and Nâ€terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. European Journal of Heart Failure, 2012, 14, 1338-1347.	2.9	181
120	Novel biomarkers in chronic heart failure. Nature Reviews Cardiology, 2012, 9, 347-359.	6.1	108
121	Inflammation and Atherosclerosis. , 2012, , .		6
122	IL-33/ST2 axis in inflammation and immunopathology. Immunologic Research, 2012, 52, 89-99.	1.3	230
123	Lysophosphatidic acid increases soluble ST2 expression in mouse lung and human bronchial epithelial cells. Cellular Signalling, 2012, 24, 77-85.	1.7	22
124	Biochemical markers in heart failure. Journal of Cardiology, 2012, 59, 1-7.	0.8	50
125	The Use of Biomarkers in the Patient with Heart Failure. Current Cardiology Reports, 2013, 15, 372.	1.3	34
126	Positioning of Inflammatory Biomarkers in the Heart Failure Landscape. Journal of Cardiovascular Translational Research, 2013, 6, 485-492.	1.1	66
127	Neutrophil gelatinase-associated lipocalin as diagnostic and prognostic tool for cardiovascular disease and heart failure. Expert Opinion on Medical Diagnostics, 2013, 7, 209-220.	1.6	11
128	The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers. Current Heart Failure Reports, 2013, 10, 441-449.	1.3	27
129	Circulating Biomarkers in Patients with Heart Failure and Preserved Ejection Fraction. Current Heart Failure Reports, 2013, 10, 350-358.	1.3	27
130	Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 1359-1370.	0.7	43
131	Soluble ST2 Serum Concentration and Renal Function in HeartÂFailure. Journal of Cardiac Failure, 2013, 19, 768-775.	0.7	87

#	Article	IF	Citations
132	Soluble ST2 as a Biomarker for Detecting Stable Heart Failure With a Normal Ejection Fraction in Hypertensive Patients. Journal of Cardiac Failure, 2013, 19, 163-168.	0.7	74
133	Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis. Cytokine, 2013, 62, 272-277.	1.4	28
134	Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. Journal of Molecular and Cellular Cardiology, 2013, 60, 16-26.	0.9	145
135	Soluble ST2 levels are not associated with secondary cardiovascular events and vulnerable plaque phenotype in patients with carotid artery stenosis. Atherosclerosis, 2013, 231, 48-53.	0.4	20
136	Measurement of sST2 is comparable to PlGF in the diagnosis of early-onset pre-eclampsia. Pregnancy Hypertension, 2013, 3, 115-117.	0.6	6
137	Temporal changes of soluble <scp>ST</scp>2 after cardiovascular interventions. European Journal of Clinical Investigation, 2013, 43, 113-120.	1.7	18
138	High plasma levels of soluble ST2 but not its ligand IL-33 is associated with severe forms of pediatric dengue. Cytokine, 2013, 61, 766-771.	1.4	33
139	ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside. Journal of Cardiovascular Translational Research, 2013, 6, 493-500.	1.1	77
140	The Presage^{Â®}ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Review of Molecular Diagnostics, 2013, 13, 13-30.	1.5	79
141	Biochemistry and biology: Heart-to-heart to investigate cardiac progenitor cells. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2459-2469.	1.1	7
142	Advances in the detection and quantification of candidate and established biomarkers in heart failure. Romanian Journal of Laboratory Medicine, 2013, 21, .	0.1	2
143	Natriuretic peptides, novel biomarkers, and the prediction of future events. European Heart Journal, 2013, 34, 419-421.	1.0	2
144	Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening. Journal of the American Heart Association, 2013, 2, e000399.	1.6	66
145	Soluble ST2 Is Associated with All-Cause and Cardiovascular Mortality in a Population-Based Cohort: The Dallas Heart Study. Clinical Chemistry, 2013, 59, 536-546.	1.5	58
146	Soluble ST2 in Ambulatory Patients With Heart Failure. Circulation: Heart Failure, 2013, 6, 1172-1179.	1.6	114
147	ST2 in Emergency Department Patients With Noncardiac Dyspnea. Academic Emergency Medicine, 2013, 20, 1207-1210.	0.8	15
148	Levels of interleukinÂ33 and soluble suppression of tumorigenicityÂ2 in acute ischemic stroke. Clinical and Experimental Neuroimmunology, 2013, 4, 339-347.	0.5	1
149	Biomarkers of Cardiovascular Stress and Incident Chronic Kidney Disease. Clinical Chemistry, 2013, 59, 1613-1620.	1.5	91

#	Article	IF	Citations
150	Soluble ST2 predicts elevated SBP in the community. Journal of Hypertension, 2013, 31, 1431-1436.	0.3	42
151	Soluble ST2 protein in chronic heart failure is independent of traditional factors. Archives of Medical Science, 2013, 1, 21-26.	0.4	25
153	A Role for Soluble ST2 in Vascular Remodeling Associated with Obesity in Rats. PLoS ONE, 2013, 8, e79176.	1.1	37
154	Right Ventricular Failure and Pathobiology in Patients with Congenital Heart Disease â€“ Implications for Long-Term Follow-Up. Frontiers in Pediatrics, 2013, 1, 37.	0.9	22
155	A Novel Cardiac Bio-Marker: ST2: A Review. Molecules, 2013, 18, 15314-15328.	1.7	114
156	Soluble ST2 and Interleukin-33 Levels in Coronary Artery Disease: Relation to Disease Activity and Adverse Outcome. PLoS ONE, 2014, 9, e95055.	1.1	72
157	Cardiac Biomarkers. , 2014, , .		7
158	Biomarkers in Heart Failure. International Heart Journal, 2014, 55, 474-481.	0.5	31
159	Biomarkers in Hypertension and Their Relationship with Myocardial Target-Organ Damage. Current Hypertension Reports, 2014, 16, 502.	1.5	3
160	Biomarkers of acute rejection following cardiac transplantation. Biomarkers in Medicine, 2014, 8, 815-832.	0.6	10
161	The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects. Journal of Human Hypertension, 2014, 28, 432-437.	1.0	29
162	Novel biomarkers in heart failure: usefulness in clinical practice. Expert Review of Cardiovascular Therapy, 2014, 12, 311-321.	0.6	9
163	Emerging Biomarkers in Heart Failure and Cardiac Cachexia. International Journal of Molecular Sciences, 2014, 15, 23878-23896.	1.8	36
164	Associations between Variants in IL-33/ST2 Signaling Pathway Genes and Coronary Heart Disease Risk. International Journal of Molecular Sciences, 2014, 15, 23227-23239.	1.8	17
165	Interleukin-1 Receptor-Related Protein ST2 and Mitral Valve Repair Outcome in Patients with Chronic Degenerative Mitral Regurgitation. Thoracic and Cardiovascular Surgeon, 2014, 62, 047-051.	0.4	6
166	Soluble ST2, a modulator of the inflammatory response, in preterm and term labor. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 111-121.	0.7	24
167	Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction. Biomarkers in Medicine, 2014, 8, 95-106.	0.6	15
168	Serum Soluble ST2 as Diagnostic Marker of Systemic Inflammatory Reactive Syndrome of Bacterial Etiology in Children. Pediatric Infectious Disease Journal, 2014, 33, 199-203.	1.1	10

#	Article	IF	Citations
169	Levels of Galectin-3 and Stimulation Expressed Gene 2 in the peritoneal fluid of women with endometriosis: a pilot study. Gynecological Endocrinology, 2014, 30, 877-880.	0.7	12
170	Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study. Heart Rhythm, 2014, 11, 2167-2175.	0.3	46
171	ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality. Heart, 2014, 100, 1715-1721.	1.2	42
172	Using ST2 in cardiovascular patients: a review. Future Cardiology, 2014, 10, 525-539.	0.5	59
173	Increased Soluble ST2 Predicts Long-term Mortality in Patients with Stable Coronary Artery Disease: Results from the Ludwigshafen Risk and Cardiovascular Health Study. Clinical Chemistry, 2014, 60, 530-540.	1.5	102
174	Role of point of care - ST ₂ , Galectin-3 and adrenomedullin in the evaluation and treatment of emergency patients. International Journal of Critical Illness and Injury Science, 2014, 4, 261.	0.2	2
175	Novel Biomarkers in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 471-479.	1.0	17
176	Natriuretic Peptides in Heart Failure. Clinical Chemistry, 2014, 60, 1040-1046.	1.5	21
177	I-L-C-2 it: type 2 immunity and group 2 innate lymphoid cells in homeostasis. Current Opinion in Immunology, 2014, 31, 58-65.	2.4	48
178	IFN-Î³ Directly Controls IL-33 Protein Level through a STAT1- and LMP2-dependent Mechanism. Journal of Biological Chemistry, 2014, 289, 11829-11843.	1.6	38
179	Biomarkers of Coronary Artery Disease: The Promise of the Transcriptome. Current Cardiology Reports, 2014, 16, 513.	1.3	29
180	Overview of Cardiac Markers in Heart Disease. Clinics in Laboratory Medicine, 2014, 34, 1-14.	0.7	10
181	AXL receptor tyrosine kinase is increased in patients with heart failure. International Journal of Cardiology, 2014, 173, 402-409.	0.8	42
182	Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Failure Reviews, 2014, 19, 369-381.	1.7	44
183	Soluble ST2 and N-terminal pro-Brain Natriuretic Peptide Combination. Circulation Journal, 2014, 78, 436-442.	0.7	31
184	ST2: the biomarker at the heart of GVHD severity. Blood, 2015, 125, 10-11.	0.6	14
185	sST2 levels are associated with allâ€cause mortality in anticoagulated patients with atrial fibrillation. European Journal of Clinical Investigation, 2015, 45, 899-905.	1.7	19
186	Can Serum ST2 Levels Be Used as a Marker of Fibrosis in Chronic Hepatitis B Infection?. Medicine (United States), 2015, 94, e1889.	0.4	18

#	Article	IF	Citations
187	Biomarkers in Acute Decompensated Heart Failure. Clinical Medicine Insights Therapeutics, 2015, 7, CMT.S18476.	0.4	0
188	Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arquivos Brasileiros De Cardiologia, 2015, 106, 145-52.	0.3	73
189	Serum Concentrations of Interleukin-33 and its Soluble Receptor sST2 in Patients with Persistent Atrial Fibrillation. Journal of Molecular Biomarkers & Diagnosis, 2015, 06, .	0.4	0
190	Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency. Journal of Korean Medical Science, 2015, 30, 569.	1.1	28
191	Combined Biomarker Analysis for Risk of Acute Kidney Injury in Patients with ST-Segment Elevation Myocardial Infarction. PLoS ONE, 2015, 10, e0125282.	1.1	37
192	Elevated Plasma Soluble ST2 Is Associated with Heart Failure Symptoms and Outcome in Aortic Stenosis. PLoS ONE, 2015, 10, e0138940.	1.1	47
193	Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides â€“ The Case for Soluble ST2. European Cardiology Review, 2015, 10, 37.	0.7	8
194	Stressed hearts inflame the body (in a good way). Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7113-7114.	3.3	4
195	Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Molecular Diagnosis and Therapy, 2015, 19, 141-158.	1.6	7
196	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. Canadian Journal of Cardiology, 2015, 31, 3-16.	0.8	96
197	Actual position of interleukin(IL)-33 in atherosclerosis and heart failure: Great Expectations or En attendant Godot?. Perfusion (United Kingdom), 2015, 30, 356-374.	0.5	5
198	Inflammatory Biomarkers in Post-infarction Heart Failure and Cardiac Remodeling. , 2015, , 105-116.		0
199	ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients. Journal of Cardiac Failure, 2015, 21, 355-361.	0.7	31
200	ST2 and Patient Prognosis in Chronic Heart Failure. American Journal of Cardiology, 2015, 115, 64B-69B.	0.7	53
201	The role of IL-33/ST2L signals in the immune cells. Immunology Letters, 2015, 164, 11-17.	1.1	62
203	Association of IL33/ST2 signal pathway gene polymorphisms with myocardial infarction in a Chinese Han population. Journal of Huazhong University of Science and Technology [Medical Sciences], 2015, 35, 16-20.	1.0	7
204	Soluble ST2 in Ventricular Dysfunction. Advances in Clinical Chemistry, 2015, 69, 139-159.	1.8	8
205	Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure. International Journal of Cardiology, 2015, 178, 284-291.	0.8	26

#	Article	IF	Citations
206	Concurrent Detection of Cellular and Molecular Cancer Markers Using an Immunomagnetic Flow System. Analytical Chemistry, 2015, 87, 10205-10212.	3.2	15
207	Current applications of biomarkers in cardiomyopathies. Expert Review of Cardiovascular Therapy, 2015, 13, 825-837.	0.6	13
208	Elevations of inflammatory markers PTX3 and sST2 after resuscitation from cardiac arrest are associated with multiple organ dysfunction syndrome and early death. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1847-57.	1.4	24
209	Giant magnetoresistive-based biosensing probe station system for multiplex protein assays. Biosensors and Bioelectronics, 2015, 70, 61-68.	5.3	68
210	ST2 marker might help to stratify in-hospital high risk patients with Tako-tsubo cardiomyopathy. European Journal of Internal Medicine, 2015, 26, 144-145.	1.0	5
211	Soluble ST2 may possess special superiority as a risk predictor in heart failure patients. International Journal of Cardiology, 2015, 186, 146-147.	0.8	5
212	Soluble ST2 Testing in the General Population. American Journal of Cardiology, 2015, 115, 22B-25B.	0.7	15
213	ST2 in Heart Failure: Where Does This New Marker Fit in?. Current Emergency and Hospital Medicine Reports, 2015, 3, 55-61.	0.6	0
214	The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood, 2015, 125, 3183-3192.	0.6	133
215	ST2 and Prognosis in Acutely Decompensated Heart Failure: TheÂInternational ST2 Consensus Panel. American Journal of Cardiology, 2015, 115, 26B-31B.	0.7	75
216	Soluble ST2â€”Analytical Considerations. American Journal of Cardiology, 2015, 115, 8B-21B.	0.7	86
217	NGAL and ST2 levels in ambulatory patients with chronic heart failure. Clinical and echocardiographic correlates. Scandinavian Cardiovascular Journal, 2015, 49, 213-219.	0.4	7
218	The Current and Potential Clinical Relevance of Heart Failure Biomarkers. Current Heart Failure Reports, 2015, 12, 318-327.	1.3	10
219	Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction?. Clinica Chimica Acta, 2015, 443, 9-16.	0.5	24
220	Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure. International Journal of Cardiology, 2015, 179, 378-384.	0.8	31
221	Soluble ST2 in heart failure. Clinica Chimica Acta, 2015, 443, 57-70.	0.5	114
222	Toward an integrated pipeline for protein biomarker development. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 677-686.	1.1	56
223	Association of circulating levels of RANTES and â^'403G/A promoter polymorphism to acute heart failure after STEMI and to cardiogenic shock. Clinical and Experimental Medicine, 2015, 15, 405-414.	1.9	9

#	Article	IF	Citations
224	Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure. Chinese Medical Journal, 2016, 129, 570-577.	0.9	10
225	Cardiac biomarkers in pediatric heart disease: A state of art review. World Journal of Cardiology, 2016, 8, 719.	0.5	21
226	Identification of disturbed pathways in heart failure based on Gibbs sampling and pathway enrichment analysis. Genetics and Molecular Research, 2016, 15, .	0.3	6
227	Soluble ST2 Levels and Left Ventricular Structure and Function in Patients With Metabolic Syndrome. Annals of Laboratory Medicine, 2016, 36, 542-549.	1.2	12
228	Immunological Biomarkers for Patient Stratification. , 2016, , 327-361.		0
229	Cell death and inflammation: the case for <scp>IL</scp>â€1 family cytokines as the canonical <scp>DAMP</scp>s of the immune system. FEBS Journal, 2016, 283, 2599-2615.	2.2	147
230	Elevated ST2 Distinguishes Incidences of Pediatric Heart and Small Bowel Transplant Rejection. American Journal of Transplantation, 2016, 16, 938-950.	2.6	34
232	Molecular and Digital Biomarker Supported Decision Making in Clinical Studies in Cardiovascular Indications. Archiv Der Pharmazie, 2016, 349, 399-409.	2.1	9
233	Diagnostic performance and reference values of novel biomarkers of paediatric heart failure. Heart, 2016, 102, 1633-1639.	1.2	48
234	Biologic Variability of Soluble ST2 in Patients With Stable Chronic Heart Failure and Implications for Monitoring. American Journal of Cardiology, 2016, 118, 95-98.	0.7	18
235	Usefulness of the thrombolysis in myocardial infarction risk index in acute heart failure: a pilot study. American Journal of Emergency Medicine, 2016, 34, 2351-2355.	0.7	3
236	Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure. Current Heart Failure Reports, 2016, 13, 207-218.	1.3	17
237	Prognostic Value of Baseline and ChangesÂin Circulating Soluble ST2 LevelsÂand the Effects of Nesiritide in Acute Decompensated Heart Failure. JACC: Heart Failure, 2016, 4, 68-77.	1.9	45
238	The soluble receptor ST2 is positively associated with occupational exposure to radiation. International Journal of Radiation Biology, 2016, 92, 87-93.	1.0	4
239	Galectin-3 and Soluble ST2 and Kidney Function Decline in Older Adults: The Cardiovascular Health Study (CHS). American Journal of Kidney Diseases, 2016, 67, 994-996.	2.1	22
240	Soluble form of the ST2 gene product exhibits growth promoting activity in NIH-3T3 cells. Biochemistry and Biophysics Reports, 2016, 5, 8-15.	0.7	11
241	Short Stay Management of Acute Heart Failure. Contemporary Cardiology, 2017, , .	0.0	0
242	Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Current Heart Failure Reports, 2017, 14, 106-116.	1.3	16

#	Article	IF	Citations
243	Meta-Analysis of Soluble Suppression ofÂTumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 2017, 5, 287-296.	1.9	104
244	Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. Biochemical Pharmacology, 2017, 138, 73-80.	2.0	50
245	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726.	5.2	99
246	Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome. Critical Care Medicine, 2017, 45, e666-e673.	0.4	25
247	Role of the IL-33-ST2 axis in sepsis. Military Medical Research, 2017, 4, 3.	1.9	45
248	Soluble Urokinase-Type Plasminogen Activator Receptor Improves RiskÂPrediction in Patients With ChronicÂHeartÂFailure. JACC: Heart Failure, 2017, 5, 268-277.	1.9	37
249	Effects of obesity on IL-33/ST2 system in heart, adipose tissue and liver: study in the experimental model of Zucker rats. Experimental and Molecular Pathology, 2017, 102, 354-359.	0.9	13
250	Soluble <scp>ST</scp>2 predicts 1â€year outcome in patients undergoing transcatheter aortic valve implantation. European Journal of Clinical Investigation, 2017, 47, 149-157.	1.7	30
251	Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device. Lab on A Chip, 2017, 17, 415-428.	3.1	20
252	Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2378-2388.	1.2	108
253	Immune mechanisms in heart failure. European Journal of Heart Failure, 2017, 19, 1379-1389.	2.9	170
254	ST2 predicts survival in patients undergoing transcatheter aortic valve implantation. International Journal of Cardiology, 2017, 244, 87-92.	0.8	17
255	Soluble ST2 for Risk Stratification and the Prediction of Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 986-993.	0.7	23
256	Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review. Cardiology, 2017, 136, 192-203.	0.6	16
257	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 280-286.	1.9	127
258	Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. International Journal of Cardiology, 2017, 226, 53-59.	0.8	51
259	Editorial commentary: Biomarkers in heart failure, between scientific scrutiny and exploration. Trends in Cardiovascular Medicine, 2017, 27, 134-135.	2.3	0
260	Comparison Between Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emergency Department With Chest Pain. Annals of Laboratory Medicine, 2017, 37, 137-146.	1.2	20

#	Article	IF	Citations
261	The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Frontiers in Immunology, 2017, 8, 475.	2.2	425
262	IL-33-ST2 Axis in Liver Disease: Progression and Challenge. Mediators of Inflammation, 2017, 2017, 1-8.	1.4	24
263	Cardiokines as Modulators of Stress-Induced Cardiac Disorders. Advances in Protein Chemistry and Structural Biology, 2017, 108, 227-256.	1.0	27
264	Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure. Anatolian Journal of Cardiology, 2017, 18, 200-205.	0.5	7
265	Redefining biomarkers in heart failure. Heart Failure Reviews, 2018, 23, 237-253.	1.7	23
266	Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial. Contemporary Clinical Trials, 2018, 66, 45-50.	0.8	7
267	Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis. Heart Asia, 2018, 10, e010980.	1.1	9
268	Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. International Journal of Cardiology, 2018, 257, 188-192.	0.8	32
269	GDFâ€15 is a better complimentary marker for risk stratification of arrhythmic death in nonâ€ischaemic, dilated cardiomyopathy than soluble ST 2. Journal of Cellular and Molecular Medicine, 2018, 22, 2422-2429.	1.6	20
270	Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 105-110.	0.9	14
271	ST2: Current status. Indian Heart Journal, 2018, 70, S96-S101.	0.2	35
272	Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia â€“ a longitudinal study. Journal of Maternal-Fetal and Neonatal Medicine, 2018, 31, 418-432.	0.7	26
273	Association of soluble ST2 with functional capacity in outpatients with heart failure. Herz, 2018, 43, 455-460.	0.4	12
274	Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and Nâ€terminal proâ€brain natriuretic peptide. Journal of Clinical Laboratory Analysis, 2018, 32, .	0.9	6
275	Proteomic Biomarkers of Heart Failure. Heart Failure Clinics, 2018, 14, 93-107.	1.0	17
276	Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction â€“ A multicenter study. Indian Heart Journal, 2018, 70, S79-S84.	0.2	17
277	IL-1 receptor like 1 protects against alcoholic liver injury by limiting NF-ÎºB activation in hepatic macrophages. Journal of Hepatology, 2018, 68, 109-117.	1.8	22
278	Magnitude of Soluble ST2 as a Novel Biomarker for Acute Aortic Dissection. Circulation, 2018, 137, 259-269.	1.6	80

#	Article	IF	Citations
279	Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction. Chinese Medical Journal, 2018, 131, 1282-1288.	0.9	11
280	OBSOLETE: Biomarkers: Heart Failure. , 2018, , .		0
281	OBSOLETE: Biomarkers in Heart Failure, Use of. , 2018, , .		0
282	ST2 and Prognosis in ChronicÂHeartÂFailure. Journal of the American College of Cardiology, 2018, 72, 2321-2323.	1.2	11
283	IL-33/ST2 Axis in Organ Fibrosis. Frontiers in Immunology, 2018, 9, 2432.	2.2	145
284	Preoperative serum ST2 level predicts acute kidney injury after adult cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1114-1123.e2.	0.4	19
285	Biomarkers: Heart Failure. , 2018, , 315-322.		1
286	Biomarkers in Heart Failure, Use of. , 2018, , 293-302.		0
287	Inflammatory Mediators in Heart Failure. , 2018, , 33-50.		0
288	MicroRNAs in pathophysiology of acute myocardial infarction and cardiogenic shock. Bratislava Medical Journal, 2018, 119, 341-347.	0.4	14
289	Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scientific Reports, 2018, 8, 10328.	1.6	6
290	Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer, 2018, 18, 102.	1.1	50
291	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 11, e004446.	1.6	58
292	Galectinâ€3 and ST2 as predictors of therapeutic success in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1164-1169.	0.7	6
293	Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study. Journal of the American Heart Association, 2019, 8, e012200.	1.6	23
294	Elevations in Circulating sST2 Levels Are Associated With In-Hospital Mortality and Adverse Clinical Outcomes After Blunt Trauma. Journal of Surgical Research, 2019, 244, 23-33.	0.8	12
295	Soluble ST2 links inflammation to outcome after subarachnoid hemorrhage. Annals of Neurology, 2019, 86, 384-394.	2.8	16
296	New Cardiovascular Biomarkers in Ischemic Heart Diseaseâ€"GDF-15, A Probable Predictor for Ejection Fraction. Journal of Clinical Medicine, 2019, 8, 924.	1.0	17

#	Article	IF	Citations
297	A multiplex analysis of sepsis mediators during human septic shock: a preliminary study on myocardial depression and organ failures. Annals of Intensive Care, 2019, 9, 64.	2.2	24
298	Clinical and Prognostic Significance of sST2 in HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2193-2203.	1.2	110
299	Cytokines in heart failure. Advances in Clinical Chemistry, 2019, 93, 63-113.	1.8	25
300	Using Soluble ST2 to Predict Adverse Postoperative Outcomes in Patients with Impaired Left Ventricular Function Undergoing Coronary Bypass Surgery. Medicina (Lithuania), 2019, 55, 572.	0.8	3
301	Cardiac and Stress Biomarkers and Chronic Kidney Disease Progression: The CRIC Study. Clinical Chemistry, 2019, 65, 1448-1457.	1.5	29
302	Soluble ST2 and Galectin-3 and Progression of CKD. Kidney International Reports, 2019, 4, 103-111.	0.4	41
303	Prognostic value of soluble ST2 in adults with congenital heart disease. Heart, 2019, 105, 999-1006.	1.2	22
304	Irregular pacing of ventricular cardiomyocytes induces proâ€fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor. European Journal of Heart Failure, 2019, 21, 482-491.	2.9	17
305	Dilated cardiomyopathy. Nature Reviews Disease Primers, 2019, 5, 32.	18.1	347
307	Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction. Journal of Molecular and Cellular Cardiology, 2019, 130, 216-233.	0.9	14
308	Cardiac biomarkers in pediatric cardiomyopathy: Study design and recruitment results from the Pediatric Cardiomyopathy Registry. Progress in Pediatric Cardiology, 2019, 53, 1-10.	0.2	7
309	Heart Failure, the Inflammasome, andÂInterleukin-1Î². Journal of the American College of Cardiology, 2019, 73, 1026-1028.	1.2	6
310	IL-33trap is a novel IL-33â€“neutralizing biologic that inhibits allergic airway inflammation. Journal of Allergy and Clinical Immunology, 2019, 144, 204-215.	1.5	45
311	ST2 in heart failure with preserved and reduced ejection fraction. Scandinavian Cardiovascular Journal, 2019, 53, 21-27.	0.4	40
312	Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making. Current Heart Failure Reports, 2019, 16, 274-284.	1.3	10
313	Biomarkers to Assess and Guide the Management of Heart Failure. , 2019, , 97-108.		0
314	Acute Fulminant Myocarditis. , 2019, , 199-203.e2.		2
315	Elevated Sera sST2 Is Associated With Heart Failure in Men â‰50ÂYears Old With Myocarditis. Journal of the American Heart Association, 2019, 8, e008968.	1.6	62

#	Article	IF	Citations
316	Different ST2 Serum Concentrations in Asymptomatic and Symptomatic Carotid Artery Stenosis. Annals of Vascular Surgery, 2019, 56, 240-245.	0.4	0
317	sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure. Acta Cardiologica, 2020, 75, 739-747.	0.3	12
318	Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases. Metabolic Syndrome and Related Disorders, 2020, 18, 10-30.	0.5	50
319	Various aspects of inflammation in heart failure. Heart Failure Reviews, 2020, 25, 537-548.	1.7	45
320	Reappraisal of Inflammatory Biomarkers in Heart Failure. Current Heart Failure Reports, 2020, 17, 9-19.	1.3	21
321	Soluble ST2 protein as a new biomarker in patientswith precapillary pulmonary hypertension. Archives of Medical Science, 2020, , .	0.4	4
322	Identifying the RNA signatures of coronary artery disease from combined lncRNA and mRNA expression profiles. Genomics, 2020, 112, 4945-4958.	1.3	11
323	The IL-1 family cytokines and receptors in autoimmune diseases. Autoimmunity Reviews, 2020, 19, 102617.	2.5	87
324	Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials. Digital Biomarkers, 2020, 4, 45-59.	2.2	8
325	Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups. Journal of Clinical Laboratory Analysis, 2020, 34, e23461.	0.9	5
326	Utilizing biomarkers associated with cardiovascular events in atrial fibrillation: informing a precision medicine response. Expert Review of Precision Medicine and Drug Development, 2020, 5, 331-345.	0.4	0
327	Combined use of high-sensitivity ST2 and NT-proBNP for predicting major adverse cardiovascular events in coronary heart failure. Annals of Palliative Medicine, 2020, 9, 1976-1989.	0.5	7
328	Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure. Journal of International Medical Research, 2020, 48, 030006052094786.	0.4	4
330	Circulating biomarkers in the early detection of hypertensive heart disease: usefulness in the developing world. Cardiovascular Diagnosis and Therapy, 2020, 10, 296-304.	0.7	8
331	Altered behavior in mice overexpressing soluble ST2. Molecular Brain, 2020, 13, 74.	1.3	11
332	Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers. Disease Markers, 2020, 2020, 1-21.	0.6	57
333	Oxidative stress and inflammation: Early predictive indicators of multiple recurrent coronary inâ€stent chronic total occlusions in elderly patients after coronary stenting. IUBMB Life, 2020, 72, 1023-1033.	1.5	9
334	Pharmacological interventions for heart failure in people with chronic kidney disease. The Cochrane Library, 2020, 2020, CD012466.	1.5	7

#	Article	IF	Citations
335	Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. Heart, 2020, 106, 342-349.	1.2	89
336	Biological functions and therapeutic opportunities of soluble cytokine receptors. Cytokine and Growth Factor Reviews, 2020, 55, 94-108.	3.2	36
337	Cardiac Biomarkers for Risk Stratification of Acute Kidney Injury After Pediatric Cardiac Surgery. Annals of Thoracic Surgery, 2021, 111, 191-198.	0.7	16
338	Challenges and Perspectives on Biosensors for Highly Sensitive Quantification of Salivary Troponins: A Review. IEEE Sensors Journal, 2021, 21, 13976-13984.	2.4	8
339	Serum cytokine levels associated with myocardial injury in systemic lupus erythematosus. Rheumatology, 2021, 60, 2010-2021.	0.9	11
340	Impact of lipophilic vs hydrophilic statins on the clinical outcome and biomarkers of remodelling in heart failure patients: A prospective comparative randomized study. British Journal of Clinical Pharmacology, 2021, 87, 2855-2866.	1.1	7
341	Plasma soluble suppression of tumorigenicity 2 and depression after acute ischemic stroke. European Journal of Neurology, 2021, 28, 868-876.	1.7	6
342	Gender-Related Differences in Heart Failure Biomarkers. Frontiers in Cardiovascular Medicine, 2020, 7, 617705.	1.1	31
343	A combination of <scp>NLR</scp> and <scp>sST2</scp> is associated with adverse cardiovascular events in patients with myocardial injury induced by moderate to severe acute carbon monoxide poisoning. Clinical Cardiology, 2021, 44, 401-406.	0.7	3
344	Soluble ST2 and Galectin-3 as Predictors of Chronic Kidney Disease Progression and Outcomes. American Journal of Nephrology, 2021, 52, 119-130.	1.4	14
345	Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1289-1297.	0.9	9
346	Cardiac T-Tubule cBIN1-Microdomain, a Diagnostic Marker and Therapeutic Target of Heart Failure. International Journal of Molecular Sciences, 2021, 22, 2299.	1.8	5
347	Elevated levels of soluble ST2 but not galectin-3 are associated with increased risk of mortality in hemodialysis patients. Kidney Research and Clinical Practice, 2021, 40, 109-119.	0.9	2
348	Soluble ST2 levels for predicting the presence and severity of metabolic syndrome. Endocrine Connections, 2021, 10, 336-344.	0.8	4
349	Lack of prognostic significance for major adverse cardiac events of soluble suppression of tumorigenicity 2 levels in patients with ST-segment elevation myocardial infarction. Cardiology Journal, 2021, 28, 244-254.	0.5	3
350	Bending Primordial Trajectories Away From Heart Failure. Journal of the American Society of Echocardiography, 2021, 34, 401-404.	1.2	0
351	Comparison of Soluble ST2, Pentraxin-3, Galectin-3, and High-Sensitivity Troponin T of Cardiovascular Outcomes in Patients With Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2021, 27, 1240-1250.	0.7	10
352	Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2021, 8, 653312.	1.1	4

#	Article	IF	Citations
353	A possible role for ST2 as prognostic biomarker for COVID-19. Vascular Pharmacology, 2021, 138, 106857.	1.0	22
354	Impact of Midregional Nâ€Terminal Proâ€“Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study. Journal of the American Heart Association, 2021, 10, e020917.	1.6	6
355	Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 697837.	1.1	31
356	Prognostic value of serum soluble ST2 in stable coronary artery disease: a prospective observational study. Scientific Reports, 2021, 11, 15203.	1.6	5
357	Role of Interleukin-1 Receptor-Like 1 (ST2) in Cerebrovascular Disease. Neurocritical Care, 2021, 35, 887-893.	1.2	6
358	Inflammatory Cytokines, Immune Cells, and Organ Interactions in Heart Failure. Frontiers in Physiology, 2021, 12, 695047.	1.3	22
359	Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166148.	1.8	14
360	Biomarkers of graft-vs-host disease: Understanding and applications for the future. World Journal of Transplantation, 2021, 11, 335-343.	0.6	8
361	Effect of heart failure and malnutrition, alone and in combination, on rehabilitation effectiveness in patients with hip fracture. Clinical Nutrition ESPEN, 2021, 44, 356-366.	0.5	6
362	Biomarkers in Acute Heart Failure Syndromes: An Update. Current Cardiology Reviews, 2021, 17, .	0.6	1
363	Cardiac Endocrinology. JACC Basic To Translational Science, 2020, 5, 949-960.	1.9	17
364	IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Journal of Clinical Investigation, 2007, 117, 1538-1549.	3.9	859
365	Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. Journal of Clinical Investigation, 2013, 123, 4208-4218.	3.9	101
366	Soluble ST2 Levels Are Associated with Bleeding in Patients with Severe Leptospirosis. PLoS Neglected Tropical Diseases, 2009, 3, e453.	1.3	74
367	The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel â€˜Alarminâ€™?. PLoS ONE, 2008, 3, e3331.	1.1	990
368	Daily Exposure to Dust Alters Innate Immunity. PLoS ONE, 2012, 7, e31646.	1.1	31
369	Soluble ST2 Associates with Diabetes but Not Established Cardiovascular Risk Factors: A New Inflammatory Pathway of Relevance to Diabetes?. PLoS ONE, 2012, 7, e47830.	1.1	56
370	Membrane Translocation of IL-33 Receptor in Ventilator Induced Lung Injury. PLoS ONE, 2015, 10, e0121391.	1.1	14

#	Article	IF	Citations
371	The role of interleukins in heart failure with reduced ejection fraction. Anatolian Journal of Cardiology, 2019, 22, 287-299.	0.5	24
372	Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. Cardiac Failure Review, 2020, 6, 1-7.	1.2	8
374	Novel Biomarkers in Cardiovascular Disease: A Review. Indonesian Biomedical Journal, 2010, 2, 66.	0.2	1
375	The Predictive Role for ST2 in Patients with Acute Coronary Syndromes and Heart Failure. Current Medicinal Chemistry, 2020, 27, 4479-4493.	1.2	9
376	Soluble ST2 as a Diagnostic and Prognostic Marker for Acute Heart Failure Syndromes. Open Biomarkers Journal, 2012, 5, 1-8.	0.1	24
377	Soluble ST2 and myocardial fibrosis in 3T cardiac magnetic resonance. Scandinavian Cardiovascular Journal, 2015, 49, 361-6.	0.4	9
378	Soluble ST2: A new and promising activity marker in ulcerative colitis. World Journal of Gastroenterology, 2011, 17, 2181.	1.4	51
379	Type 4 Cardiorenal Syndrome: Myocardial Dysfunction, Fibrosis, and Heart Failure in Patients with Chronic Kidney Disease. Journal of Clinical & Experimental Cardiology, 2012, 03, .	0.0	4
380	Systemic inflammation and oxidative stress contribute to acute kidney injury after transcatheter aortic valve implantation. Cardiology Journal, 2022, 29, 824-835.	0.5	8
381	Soluble ST2 protein in the short-term prognosis after hospitalisation in chronic systolic heart failure. Kardiologia Polska, 2014, 72, 725-734.	0.3	12
382	Biomarkers in the management of acute heart failure: state of the art and role in COVIDâ€19 era. ESC Heart Failure, 2021, 8, 4465-4483.	1.4	10
383	Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis. IJC Heart and Vasculature, 2021, 37, 100887.	0.6	13
384	Novel Markers of Hemodynamic Stress. , 2006, , 427-447.		0
385	Right Ventricular Dysfunction in Pulmonary Hypertension. , 2011, , 1313-1331.		0
386	Interleukin-33 and Atherosclerosis. , 2012, , 239-248.		0
387	Research of Immunology Markers of UC. , 0, , .		0
389	Diagnostic and Prognostic Biomarkers in Emergency Department Heart Failure. Contemporary Cardiology, 2012, , 125-139.	0.0	0
390	Immunological Mechanisms of Inflammation. , 2013, , 15-26.		0

#	Article	IF	Citations
391	Markers and Correlates of Right Ventricular Function with Computed Tomography, Echocardiography, and Magnetic Resonance. , 2015, , 1-38.		0
392	Effectiveness of the Suppression of Tumorigenicity 2 for Prognosis in Heart Failure: Systematic Reviews. The Journal of Health Technology Assessment, 2015, 3, 115-121.	0.2	0
393	Markers and Correlates of Right Ventricular Function with Computed Tomography, Echocardiography, and Magnetic Resonance. , 2016, , 1183-1219.		0
394	Clinical roles of soluble ST2 for the outcomes of cardiac valve operations. Research Ideas and Outcomes, 0, 2, e8849.	1.0	0
395	Diagnostic and Prognostic Biomarkers in Emergency Department Heart Failure. Contemporary Cardiology, 2017, , 145-163.	0.0	0
396	Biomarkers: New Horizon for Heart Failure Practice. , 2018, , 17-38.		0
398	The concentration of interleukin-33 in heart failure with reduced ejection fraction. Anatolian Journal of Cardiology, 2019, 21, 305-313.	0.5	7
399	Are soluble ST2 levels influenced by vitamin D and/or the seasons?. Endocrine Connections, 2019, 8, 691-700.	0.8	1
400	A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction. Open Medicine (Poland), 2020, 15, 644-653.	0.6	0
402	Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality. Experimental and Clinical Cardiology, 2012, 17, 205-9.	1.3	15
403	ST2 and Galectin-3: Ready for Prime Time?. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2016, 27, 238-52.	0.7	18
404	Role of Inflammation and Redox Status on Doxorubicin-Induced Cardiotoxicity in Infant and Adult CD-1 Male Mice. Biomolecules, 2021, 11, 1725.	1.8	16
405	Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results. International Journal of Molecular Sciences, 2021, 22, 13053.	1.8	15
406	Identification and Comparison of Potential Biomarkers by Proteomic Analysis in Traditional Chinese Medicine-Based Heart Failure Syndromes. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-11.	0.5	3
407	THE ROLE OF NT-PROBNP AND ST2 BIOMARKERS IN PATIENTS WITH ACUTE CORONARY SYNDROME. WiadomoÅ›ci Lekarskie, 2022, 75, 34-38.	0.1	1
408	Biomarker Development in Cardiology: Reviewing the Past to Inform the Future. Cells, 2022, 11, 588.	1.8	2
409	Are soluble ST2 levels influenced by vitamin D and/or the seasons?. Endocrine Connections, 2019, 8, 691-700.	0.8	1
410	Suppression of tumorigenicityâ€2 (ST2) is a promising biomarker in heart transplantation. Clinical Transplantation, 2022, 36, e14616.	0.8	2

#	Article	IF	Citations
411	Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD. Kidney360, 2022, 3, 859-871.	0.9	6
412	The roles of interleukinâ€1 receptor accessory protein in certain inflammatory conditions. Immunology, 2022, 166, 38-46.	2.0	16
413	Prognostic utility of soluble ST2 biomarker in heart failure patients with reduced ejection fraction. International Journal of Clinical Biochemistry and Research, 2022, 9, 22-27.	0.0	0
414	General Rehabilitation Program after Knee or Hip Replacement Significantly Influences Erythrocytes Oxidative Stress Markers and Serum ST2 Levels. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-11.	1.9	3
415	ST2 and galectin-3 as novel biomarkers for the prediction of future cardiovascular disease risk in preeclampsia. Journal of Obstetrics and Gynaecology, 2022, 42, 1023-1029.	0.4	3
416	Soluble ST2 and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Diseaseâ€"A 10-Year Cohort Study. Journal of Clinical Medicine, 2022, 11, 56.	1.0	7
417	Synergistic Effects of Weighted Genetic Risk Scores and Resistin and sST2 Levels on the Prognostication of Long-Term Outcomes in Patients with Coronary Artery Disease. International Journal of Molecular Sciences, 2022, 23, 4292.	1.8	1
418	Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.. Journal of Geriatric Cardiology, 2021, 18, 908-951.	0.2	6
421	Cardiac Dysfunction Biomarkers Are Associated With Potential for Successful Separation From Extracorporeal Membrane Oxygenation in Children. ASAIO Journal, 2023, 69, 198-204.	0.9	1
422	Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future. International Journal of Molecular Sciences, 2022, 23, 5680.	1.8	20
423	Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction. Cardiovascular Research, 2023, 119, 710-728.	1.8	4
424	Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus. CKJ: Clinical Kidney Journal, 2022, 15, 1915-1923.	1.4	3
426	Biomarkers in heart failure: Relevance in the clinical practice. International Journal of Cardiology, 2022, 363, 196-201.	0.8	5
427	Signaling and functions of interleukin-33 in immune regulation and diseases. , 2022, 1, 100042.		9
428	Prognostic Role of sST2 in Acute Heart Failure and COVID-19 Infectionâ€"A Narrative Review on Pathophysiology and Clinical Prospective. International Journal of Molecular Sciences, 2022, 23, 8230.	1.8	7
429	ILâ€33/ST2 pathway as upperâ€hand of inflammation in allergic asthma contributes as predictive biomarker in heart failure. ESC Heart Failure, 2022, 9, 3785-3790.	1.4	5
430	Elevated Serum Levels of IgG4 in Patients with Heart Failure with Reduced Ejection Fraction: A Prospective Controlled Study. Biology, 2022, 11, 1168.	1.3	3
431	Emerging biomarkers for the detection of cardiovascular diseases. Egyptian Heart Journal, 2022, 74, .	0.4	14

#	Article	IF	Citations
432	Advances in congestive heart failure biomarkers. Advances in Clinical Chemistry, 2023, , 205-248.	1.8	3
433	The Role of Biomarkers in Heart Failure with Preserved Ejection Fraction. , 2022, 2, 281-289.		0
434	Soluble suppression of tumorigenicity-2 in pregnancy with a small-for-gestational-age fetus and with preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2023, 36, .	0.7	4
435	Clinical application and new utility of sST2 in emergency area. Italian Journal of Emergency Medicine, 2022, 11, .	0.0	0
436	Sex and age differences in sST2 in cardiovascular disease. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
437	The soluble suppression of tumorigenicity 2 as a biomarker of early cardiac remodeling in bradycardia patients receiving permanent pacemaker therapy. Future Science OA, 2023, 9, .	0.9	0
438	Paediatric heart failure â€“ understanding the pathophysiology and the current role of cardiac biomarkers in clinical practice. Cardiology in the Young, 2023, 33, 503-513.	0.4	3
439	The serum soluble scavenger with 5 domains levels: A novel biomarker for individuals with heart failure. Frontiers in Physiology, 0, 14, .	1.3	0
441	Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure. Biomedicines, 2023, 11, 917.	1.4	9
442	A biomarker for bacteremia in pregnant women with acute pyelonephritis: soluble suppressor of tumorigenicity 2 or sST2. Journal of Maternal-Fetal and Neonatal Medicine, 2023, 36, .	0.7	0
443	Soluble ST2 predicts continuous renal replacement therapy in patients receiving venoarterial extracorporeal membrane oxygenation. Perfusion (United Kingdom), 0, , 026765912311694.	0.5	0
444	Circulating ST2: from biomarker to pathogenic mediator. Revista Espanola De Cardiologia (English Ed) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	0